Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Neumann

Showing results (1-10 of 301) with videos related to

Pageof 31
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 1, 2021
Toward Better Data Dashboards for US Drug Value AssessmentsPeter J Neumann
Health Affairs (Project Hope)|March 9, 2004
Evidence-based and value-based formulary guidelinesPeter J Neumann
Pharmacoeconomics|June 18, 2005
Health utilities in Alzheimer's disease and implications for cost-effectiveness analysisPeter J Neumann
The New England Journal of Medicine|July 19, 2013
Communicating and promoting comparative-effectiveness research findingsPeter J Neumann
Health Affairs (Project Hope)|June 8, 2006
Emerging lessons from the drug effectiveness review projectPeter J Neumann
The New England Journal of Medicine|February 17, 2012
What we talk about when we talk about health care costsPeter J Neumann
The American Journal of Managed Care|May 22, 2004
Why don't Americans use cost-effectiveness analysis?Peter J Neumann
Medical Care|June 19, 2009
Costing and perspective in published cost-effectiveness analysisPeter J Neumann
JAMA|May 5, 2011
What next for QALYs?Peter J Neumann
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 16, 2009
Lessons for health technology assessment: it is not only about the evidencePeter J Neumann
Pageof 31

Showing results (1-10 of 301) with videos related to

Sort By:
Pageof 31
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 1, 2021
Toward Better Data Dashboards for US Drug Value AssessmentsPeter J Neumann
Health Affairs (Project Hope)|March 9, 2004
Evidence-based and value-based formulary guidelinesPeter J Neumann
Pharmacoeconomics|June 18, 2005
Health utilities in Alzheimer's disease and implications for cost-effectiveness analysisPeter J Neumann
The New England Journal of Medicine|July 19, 2013
Communicating and promoting comparative-effectiveness research findingsPeter J Neumann
Health Affairs (Project Hope)|June 8, 2006
Emerging lessons from the drug effectiveness review projectPeter J Neumann
The New England Journal of Medicine|February 17, 2012
What we talk about when we talk about health care costsPeter J Neumann
The American Journal of Managed Care|May 22, 2004
Why don't Americans use cost-effectiveness analysis?Peter J Neumann
Medical Care|June 19, 2009
Costing and perspective in published cost-effectiveness analysisPeter J Neumann
JAMA|May 5, 2011
What next for QALYs?Peter J Neumann
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 16, 2009
Lessons for health technology assessment: it is not only about the evidencePeter J Neumann
Pageof 31